In our analysis, [18F]-PSMA-1007 seems to add several advantages in routine clinical applications, related to economic convenience, greater availability, and consequent higher number of performed PET/CT exams, as well as a pattern of distribution similar to [177Lu]Lu-PSMA-617 within PCa lesions, which supports its clinical use for proper selection of patients eligible for RLT. The gene discussed is FOLH1; the disease is posterior cortical atrophy.